NO330216B1 - Fremgangsmate for fremstilling av en albumin-anriket fraksjon med redusert innhold av prekallikreinaktivator (PKA). - Google Patents
Fremgangsmate for fremstilling av en albumin-anriket fraksjon med redusert innhold av prekallikreinaktivator (PKA). Download PDFInfo
- Publication number
- NO330216B1 NO330216B1 NO20052550A NO20052550A NO330216B1 NO 330216 B1 NO330216 B1 NO 330216B1 NO 20052550 A NO20052550 A NO 20052550A NO 20052550 A NO20052550 A NO 20052550A NO 330216 B1 NO330216 B1 NO 330216B1
- Authority
- NO
- Norway
- Prior art keywords
- albumin
- fraction
- pka
- solution
- filter
- Prior art date
Links
- 102000009027 Albumins Human genes 0.000 title claims abstract description 31
- 108010088751 Albumins Proteins 0.000 title claims abstract description 31
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- 239000012190 activator Substances 0.000 title abstract description 3
- 238000011049 filling Methods 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 8
- 238000005194 fractionation Methods 0.000 claims abstract description 4
- 238000010438 heat treatment Methods 0.000 claims abstract description 3
- 108010071241 Factor XIIa Proteins 0.000 claims description 20
- 238000011534 incubation Methods 0.000 claims description 11
- 238000009928 pasteurization Methods 0.000 claims description 11
- DZTHIGRZJZPRDV-UHFFFAOYSA-N N-acetyltryptophan Chemical compound C1=CC=C2C(CC(NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-UHFFFAOYSA-N 0.000 claims description 6
- 229960005480 sodium caprylate Drugs 0.000 claims description 3
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 abstract description 11
- 239000000243 solution Substances 0.000 description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 20
- 239000008215 water for injection Substances 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 239000012528 membrane Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000000758 substrate Substances 0.000 description 12
- 239000000203 mixture Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 238000000108 ultra-filtration Methods 0.000 description 8
- 108090000113 Plasma Kallikrein Proteins 0.000 description 6
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 6
- 238000010998 test method Methods 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 238000011146 sterile filtration Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 238000011026 diafiltration Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 3
- 108060005987 Kallikrein Proteins 0.000 description 3
- 102000001399 Kallikrein Human genes 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000005429 filling process Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 229960002446 octanoic acid Drugs 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000008174 sterile solution Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000010979 pH adjustment Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- KZKAYEGOIJEWQB-UHFFFAOYSA-N 1,3-dibromopropane;n,n,n',n'-tetramethylhexane-1,6-diamine Chemical compound BrCCCBr.CN(C)CCCCCCN(C)C KZKAYEGOIJEWQB-UHFFFAOYSA-N 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108010058936 Cohn fraction V Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229950007870 hexadimethrine bromide Drugs 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013026 undiluted sample Substances 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02026165 | 2002-11-25 | ||
| PCT/EP2003/013239 WO2004047859A2 (en) | 2002-11-25 | 2003-11-25 | Prekallikrein depleted plasma derived albumin fraction |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20052550D0 NO20052550D0 (no) | 2005-05-26 |
| NO20052550L NO20052550L (no) | 2005-08-12 |
| NO330216B1 true NO330216B1 (no) | 2011-03-07 |
Family
ID=32337993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20052550A NO330216B1 (no) | 2002-11-25 | 2005-05-26 | Fremgangsmate for fremstilling av en albumin-anriket fraksjon med redusert innhold av prekallikreinaktivator (PKA). |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7700732B2 (uk) |
| EP (1) | EP1565207B1 (uk) |
| JP (1) | JP4532282B2 (uk) |
| KR (1) | KR101077651B1 (uk) |
| CN (1) | CN100364609C (uk) |
| AT (1) | ATE322907T1 (uk) |
| AU (1) | AU2003292109B2 (uk) |
| BR (1) | BR0316563A (uk) |
| CA (1) | CA2506848C (uk) |
| DE (1) | DE60304603T2 (uk) |
| DK (1) | DK1565207T3 (uk) |
| ES (1) | ES2261977T3 (uk) |
| IL (1) | IL168506A (uk) |
| MX (1) | MXPA05005328A (uk) |
| NO (1) | NO330216B1 (uk) |
| PL (1) | PL375539A1 (uk) |
| PT (1) | PT1565207E (uk) |
| RS (1) | RS20050401A (uk) |
| RU (1) | RU2321421C2 (uk) |
| SI (1) | SI1565207T1 (uk) |
| UA (1) | UA77596C2 (uk) |
| WO (1) | WO2004047859A2 (uk) |
| ZA (1) | ZA200504202B (uk) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2221817B1 (es) | 2004-07-26 | 2005-10-01 | Probitas Pharma, S.A. | "soluciones de albumina humana terapeutica con baja actividad del activador de precalicreina (pka) y procedimiento de obtencion de las mismas". |
| ES2294976B1 (es) | 2007-11-12 | 2008-12-16 | Grifols, S.A. | "procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion". |
| SE1050124A1 (sv) | 2010-02-08 | 2011-08-09 | Linkoping Biocontrols Ab | Stabil lösning |
| GB201317458D0 (en) * | 2013-10-02 | 2013-11-13 | Spd Swiss Prec Diagnostics Gmbh | Improved pregnancy test device and method |
| CN107216383A (zh) * | 2017-07-13 | 2017-09-29 | 同路生物制药有限公司 | 一种人血白蛋白的制备方法及该人血白蛋白 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4251510A (en) * | 1979-08-15 | 1981-02-17 | Cutter Laboratories, Inc. | Intravenously injectable solution of plasma protein fraction free from bradykinin, kininogen and prekallikrein activators and processes for its production |
| US4378346A (en) * | 1979-08-15 | 1983-03-29 | Tankersley Donald L | Intravenously injectable solution of plasma protein fraction free from bradykinin, kininogen and prekallikrein activators and processes for its production |
| US4440679A (en) * | 1980-03-05 | 1984-04-03 | Cutter Laboratories, Inc. | Pasteurized therapeutically active protein compositions |
| EP0035204B2 (en) * | 1980-03-05 | 1991-05-22 | Miles Inc. | Pasteurized therapeutically active protein compositions |
| US4391801A (en) * | 1981-10-29 | 1983-07-05 | Cutter Laboratories, Inc. | Plasma protein fraction substantially free of acetate ions |
| AT376367B (de) * | 1983-03-16 | 1984-11-12 | Immuno Ag | Verfahren zur herstellung von therapeutisch verabreichbaren, in endbehaeltern abgefuellten plasmaderivaten |
| AT391810B (de) * | 1988-02-26 | 1990-12-10 | Immuno Ag | Verwendung von chymotrypsin zum unwirksammachen des praekallikrein-aktivators |
| JP3554796B2 (ja) * | 1988-10-31 | 2004-08-18 | 三菱ウェルファーマ株式会社 | アルブミン製剤及びその製造方法 |
| US5919907A (en) * | 1997-12-22 | 1999-07-06 | Shanbrom Technologies Llc | Preparation and utilization of a novel sterile albumin |
| US6693173B2 (en) * | 2000-12-26 | 2004-02-17 | Alpha Therapeutic Corporation | Method to remove citrate and aluminum from proteins |
-
2003
- 2003-11-25 MX MXPA05005328A patent/MXPA05005328A/es active IP Right Grant
- 2003-11-25 US US10/533,160 patent/US7700732B2/en not_active Expired - Fee Related
- 2003-11-25 EP EP03767649A patent/EP1565207B1/en not_active Revoked
- 2003-11-25 CN CNB2003801041314A patent/CN100364609C/zh not_active Expired - Fee Related
- 2003-11-25 DK DK03767649T patent/DK1565207T3/da active
- 2003-11-25 RS YUP-2005/0401A patent/RS20050401A/sr unknown
- 2003-11-25 AU AU2003292109A patent/AU2003292109B2/en not_active Ceased
- 2003-11-25 ES ES03767649T patent/ES2261977T3/es not_active Expired - Lifetime
- 2003-11-25 CA CA2506848A patent/CA2506848C/en not_active Expired - Fee Related
- 2003-11-25 PT PT03767649T patent/PT1565207E/pt unknown
- 2003-11-25 BR BR0316563-9A patent/BR0316563A/pt active Pending
- 2003-11-25 UA UAA200506246A patent/UA77596C2/uk unknown
- 2003-11-25 PL PL03375539A patent/PL375539A1/xx unknown
- 2003-11-25 RU RU2005119987/15A patent/RU2321421C2/ru not_active IP Right Cessation
- 2003-11-25 JP JP2004554458A patent/JP4532282B2/ja not_active Expired - Fee Related
- 2003-11-25 WO PCT/EP2003/013239 patent/WO2004047859A2/en active IP Right Grant
- 2003-11-25 AT AT03767649T patent/ATE322907T1/de active
- 2003-11-25 SI SI200330277T patent/SI1565207T1/sl unknown
- 2003-11-25 KR KR1020057008932A patent/KR101077651B1/ko not_active IP Right Cessation
- 2003-11-25 DE DE60304603T patent/DE60304603T2/de not_active Expired - Lifetime
-
2005
- 2005-05-10 IL IL168506A patent/IL168506A/en not_active IP Right Cessation
- 2005-05-24 ZA ZA200504202A patent/ZA200504202B/en unknown
- 2005-05-26 NO NO20052550A patent/NO330216B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1104323B1 (en) | Apparatus and method of preparation of stable, long term thrombin from plasma and thrombin formed thereby | |
| Freinkel et al. | Alcohol hypoglycemia. I. Carbohydrate metabolism of patients with clinical alcohol hypoglycemia and the experimental reproduction of the syndrome with pure ethanol | |
| EP0602173B1 (en) | Topical fibrinogen complex | |
| Heystek et al. | Contributions to the optimal use of human blood | |
| NO148142B (no) | Fremgangsmaate ved fremstilling av et blodkoaguleringsfremmende preparat fra humant blodplasma | |
| NO330216B1 (no) | Fremgangsmate for fremstilling av en albumin-anriket fraksjon med redusert innhold av prekallikreinaktivator (PKA). | |
| CA2122480A1 (en) | Reconstituted platelet membrane vesicles | |
| RU2657578C2 (ru) | Способ получения человеческого альбумина с пониженным уровнем растворенного кислорода | |
| Bangham et al. | A biological standard for measurement of blood coagulation factor VIII activity | |
| CN104402993A (zh) | 一种制备静注人免疫球蛋白的方法 | |
| CN111617031A (zh) | 一种稳定的重组人干扰素α1b滴眼液及其生产方法 | |
| JPH06505494A (ja) | Ｉｘ因子の調製 | |
| US4608254A (en) | Method for the production of therapeutically administrable plasma derivatives filled in final containers | |
| US20140155498A1 (en) | Method of Manufacture of Stable Liquid Coagulation Factors | |
| Parry et al. | Familial haemostatic defect associated with reduced prothrombin consumption | |
| Johnson et al. | Enhanced Yield of Antihemophilic Factor and von Willebrand Factor by Cryoprecipitation with Polyethylene Glycol1 | |
| Resnick et al. | Calcium-binding proteins and renal lithiasis | |
| CZ299296B6 (cs) | Lécivo transfer faktor - zpusob výroby a použití | |
| Boots et al. | The hydrogen ion concentration of joint exudates in rheumatic fever and other forms of arthritis | |
| DeVIVO et al. | Influence of human cerebrospinal fluid on blood coagulation in vitro | |
| NO175622B (uk) | ||
| US4791191A (en) | Depyrogenation of clinical albumin | |
| Wolf | Preparation and clinical use of a concentrate of human antihaemophilic factor | |
| Baird et al. | Effect of membrane filtration of antimalarial drug solutions on in vitro activity against Plasmodium falciparum | |
| Allersma et al. | Quality control programme for the preparation of small-pool lyophilized heat-treated cryoprecipitates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |